AI Article Synopsis
- Pulmonary carcinosarcoma (PC) is a rare and aggressive form of non-small cell lung cancer that typically doesn’t respond well to conventional treatments like chemotherapy and radiotherapy, resulting in a poor prognosis.
- A case study was conducted on an 88-year-old patient with PC that was deemed inoperable and had a prior history of cerebral infarction.
- The patient was treated with a combination of anlotinib (a targeted therapy) and stereotactic body radiation therapy (SBRT), showing a sustained positive response for 10 months, suggesting this combo could be a promising option for older patients with PC.
Article Abstract
Pulmonary carcinosarcoma (PC) is a rare and highly malignant type of non-small cell lung cancer (NSCLC) that is insensitive to radiotherapy and chemotherapy and has a poor prognosis. Here, we report a case of an 88-year-old patient with inoperable PC and a history of cerebral infarction who was treated with first-line anlotinib combined with stereotactic body radiation therapy (SBRT). The therapeutic response has sustained for 10 months. Our work suggests that SBRT combined with anlotinib may be a safe and effective treatment strategy for octogenarians with PC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747690 | PMC |
| http://dx.doi.org/10.2147/CMAR.S344149 | DOI Listing |
Publication Analysis
Top Keywords
first-line anlotinib
8
anlotinib combined
8
combined stereotactic
8
stereotactic body
8
body radiation
8
radiation therapy
8
pulmonary carcinosarcoma
8
therapy octogenarian
4
octogenarian pulmonary
4
carcinosarcoma pulmonary
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!